Vital

Peptides

Glow Peptide Blend: Contents, Status, and Unit Math

The Glow peptide blend mixes GHK-Cu, BPC-157 and TB-500 in one vial, often sold as 70 mg. Learn what each part is, why no approved dose exists, how Glow differs from KLOW, and how the per-component math works.

Last reviewed

The Vital angle

Vital lists Glow among its known blends and lets you save the vial as a stack with the mass of each peptide and the BAC water volume. When you log a draw in syringe units, Vital shows the amount of GHK-Cu, BPC-157 and TB-500 in that draw, and the log keeps the site, symptoms and a severity. Vital does not suggest a dose.

What the Glow peptide blend is

The Glow peptide blend is one vial of freeze-dried powder that holds three peptides: GHK-Cu, BPC-157 and TB-500. The most common seller listing is a 70 mg vial with 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500, a 5:1:1 ratio by mass. Other sellers list 35 mg and 42 mg vials, so the vial size alone does not tell you the amounts.

There is no approved human dose for the Glow blend. It is not an FDA-approved drug, none of its three parts is an FDA-approved drug, and no published controlled trial has tested the blend in people. The "dosage" numbers that rank in search come from sellers and community sites, not from a label or a trial. This guide explains what is in the vial, where the regulators stand, and how the unit math works for each part, using hypothetical numbers only.

What is in a Glow vial

Each part has its own research history, and most of it is in cells and animals.

Part Mass in a typical 70 mg listing FDA-approved drug Human evidence
GHK-Cu 50 mg No Mostly topical skin products. No published human trial of injection
BPC-157 10 mg No A few small pilot studies. Mostly preclinical
TB-500 10 mg No The FDA says it has not identified human exposure data
  • GHK-Cu is a copper-binding tripeptide found in human plasma. Reviews of GHK describe wound and skin effects, but the cosmetic studies are topical. The best-known reviews come from authors at a company that sells copper peptide products.
  • BPC-157 is a 15-amino-acid peptide. Most of the research is in cells and animals. The FDA says it has no or only limited safety information for people.
  • TB-500 is a short synthetic fragment linked to thymosin beta-4.

GHK-Cu is the largest part by mass. When you draw from a Glow vial, most of what you inject is the copper peptide. For the injected GHK-Cu evidence on its own, see GHK-Cu injection dosage. For the other two parts, see the BPC-157 and TB-500 stack guide.

Glow vs KLOW

Sellers use KLOW for the same three peptides plus KPV. The table compares the two names as sellers use them.

Glow KLOW
Parts GHK-Cu, BPC-157, TB-500 GHK-Cu, BPC-157, TB-500, KPV
Common total on listings 70 mg About 80 mg
FDA-approved No No
Tested as a blend in a human trial No No

A fourth part adds a fourth set of identity, purity and sterility questions. With more parts in one vial, it is also harder to connect a side effect to one cause. Both names are sales names, not standard formulas. Read the label for the exact vial you have. The full KLOW guide is KLOW peptide blend.

Regulatory status in 2026

The FDA keeps a page on bulk drug substances that may present significant safety risks in compounding. On the version current as of April 22, 2026, BPC-157, the TB-500 fragment and GHK-Cu for injectable routes are in the table of nominations that were withdrawn. The FDA notes a possible immunogenicity risk for each, which means a risk that the body makes an immune response to the peptide or its impurities. It also notes limited or no human safety data.

  • GHK-Cu. The FDA's 503A nominations list, updated May 14, 2026, puts GHK-Cu back in category 1 only "except for injectable routes of administration." Injected GHK-Cu, which is how Glow is used, is not covered. The FDA plans to ask its compounding advisory committee about GHK-Cu before the end of February 2027.
  • BPC-157 and TB-500. In July 2026, the FDA Pharmacy Compounding Advisory Committee voted to recommend both for the list of bulk substances that pharmacies can compound. The votes do not bind the FDA, and pharmacies cannot compound them under that list until rulemaking is final.
  • Athletes. USADA's advisory on the 2027 list says BPC-157 is prohibited under S0, and TB-500 and thymosin beta-4 under S2. A Glow vial contains both.

None of these steps is an approval. A three-part blend is a separate question from any single part. Check the FDA pages for the current position, because they change.

Glow blend bac water math, part by part

A blend changes the arithmetic. When you mix one vial, every draw holds all three parts in the same ratio. The numbers below are hypothetical round numbers that show the math. They are not a dose, not a suggestion and not a schedule.

  1. Assume a hypothetical vial holds 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500.
  2. Assume it is mixed with 5 mL of bacteriostatic water.
  3. Divide each mass by the volume. GHK-Cu is 10 mg per mL. BPC-157 and TB-500 are each 2 mg per mL.
  4. On a U-100 insulin syringe, 100 units fill 1 mL, so 10 units are 0.1 mL.
  5. Multiply each concentration by the volume of the draw.
Hypothetical draw on U-100 Volume GHK-Cu BPC-157 TB-500
5 units 0.05 mL 0.5 mg 100 mcg 100 mcg
10 units 0.10 mL 1 mg 200 mcg 200 mcg
20 units 0.20 mL 2 mg 400 mcg 400 mcg

If the same vial is mixed with less water, each mark on the syringe holds more of every part. With 2.5 mL, the 10-unit mark holds twice as much of each part as with 5 mL. This is why the water volume must be written down with the vial. Confirm every draw with your prescriber or pharmacist, in mL as well as units, before you inject.

You can run your own numbers in the free peptide calculator. For the mixing steps, see how to reconstitute peptides with BAC water. For the syringe scale, see how to read an insulin syringe for peptides and U-40 vs U-100 syringes.

Why the fixed ratio matters

The ratio cannot change after the vial is made. In a 5:1:1 vial, any draw that holds a given amount of BPC-157 or TB-500 also holds five times that mass of GHK-Cu. A larger draw to raise one part raises the other two by the same factor.

GHK-Cu also carries copper. Copper is roughly 16 percent of the mass of GHK-Cu, based on the molecular weights. No published study has measured blood copper in people who inject GHK-Cu, and no injected safety limit for it exists. This is one more reason the per-part amounts matter more than the total on the label.

How Vital records a blend

Vital can save a Glow vial as a stack. Glow is in the list of known blends, and you can also add each peptide by hand with its mass in mg. You enter the BAC water volume and your draw in syringe units. When you log a draw, Vital shows how much of each part that draw holds, and the dose log keeps the injection site, any symptoms and a severity. Vital is a tracking tool. It does not suggest a dose and does not tell you whether a blend is right for you.

If you track Glow with other compounds, see the best peptide tracker app and a peptide injection log template.

How to check a Glow vial

Most Glow vials come from sellers outside the licensed pharmacy system. The source check is the most important step. A full method is in how to check a peptide catalog source, and the label itself is covered in how to read a peptide vial label.

  1. Find the mass of each part on the label, not only the total.
  2. Ask for a certificate of analysis for the exact lot number, with a lab name and a date.
  3. Check that the certificate reports identity and purity for each of the three parts.
  4. Look for sterility and endotoxin results. Purity alone does not show that a vial is sterile.
  5. Treat "for research use only" next to human dosing advice as a red flag.
  6. Write down the lot number, the seller and the mixing date before first use.

Warning signs that need care

Because the long-term human safety of every part is unknown, watch for changes after each injection.

  • Get medical care right away for a hot, red, spreading or very painful injection site, a lump that grows, or fever.
  • Get medical care for a severe headache, vision changes, chest pain or a fast heartbeat.
  • Get emergency care for swelling of the face, lips, tongue or throat, hives over the body, or trouble breathing.

Milder site reactions are covered in peptide injection site reactions. Tell every clinician you see that you use Glow, and name all three parts.


Vital is independent and not affiliated with any peptide seller, compounder or drug maker.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Injected GHK-Cu

    The largest part of a Glow vial by mass. The FDA's category 1 entry for GHK-Cu excludes injectable routes, and the FDA notes a possible immunogenicity risk and limited human data for injection.

  • BPC-157

    Not an FDA-approved drug. The FDA notes a possible immunogenicity risk and little human safety data. An advisory committee recommendation in July 2026 does not bind the FDA.

  • TB-500

    A synthetic thymosin beta-4 fragment. The FDA says it has not identified human exposure data. USADA lists it as prohibited for athletes under S2.

  • Fixed ratio in one vial

    Every draw holds all three parts in the same ratio, so a larger draw to raise one part raises the other two. In a 5:1:1 vial most of each draw is GHK-Cu.

  • Total-only labels

    A label that shows only 70 mg does not tell you the mass of each part. Sellers also list 35 mg and 42 mg vials, so the math changes with the vial.

Frequently asked questions

  • Glow is one vial with GHK-Cu, BPC-157 and TB-500. The most common listing is 70 mg, with 50 mg of GHK-Cu and 10 mg each of BPC-157 and TB-500. Amounts change between sellers, so read the label for each part.

  • No approved human dose exists. Glow is not an FDA-approved drug, and no published controlled trial has tested the blend in people. The numbers online come from sellers and community sites. Ask a licensed prescriber before you use any peptide.

  • It depends on the water volume. Divide each part's mass by the mL of water to get mg per mL, then multiply by the draw. On a U-100 syringe, 10 units are 0.1 mL. Confirm the draw with your prescriber or pharmacist.

  • KLOW is the same three peptides as Glow plus KPV, often listed at about 80 mg in total. Neither blend is FDA-approved or tested as a blend in a human trial.

  • There is no standard volume set by a label. The water volume sets the concentration, so the same syringe mark holds a different amount with 2 mL than with 5 mL. Write the volume on your log and confirm it with a pharmacist.

  • It is not an FDA-approved drug. The FDA's category 1 entry for GHK-Cu excludes injectable routes, and BPC-157 and TB-500 are not yet on the compounding list. Products labeled for research use only are not made as drugs for people.

Sources

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  2. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act · U.S. Food and Drug Administration
  3. FDA advisory committee nominates six peptides for pharmacies to compound · National Community Pharmacists Association
  4. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · International Journal of Molecular Sciences, via PubMed
  5. Athlete Advisory: What's New on the 2027 WADA Prohibited List? · U.S. Anti-Doping Agency

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.